title: Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-α level and the efficacy of TNF-inhibitor therapy in psoriasis.
abstract: Antidrug antibodies have been shown to be associated with a loss of response during biologic therapy. Despite the potential association, there has been no report on the simultaneous monitoring of the following parameters in psoriasis: presence of neutralizing antibodies, plasma tumor necrosis factor (TNF)-α concentration, TNFi concentration and disease activity. Plasma concentrations of adalimumab, infliximab, etanercept and their respective antidrug antibodies, as well as plasma concentrations of TNF-α were measured in 77 psoriasis patients receiving biologic therapy, and the values were correlated with the clinical activity of the skin disease. Antidrug antibodies were identified in the plasma of 25% of infliximab-treated patients and 29.6% of adalimumab-treated patients, but not in the etanercept group. Clinical severity scores were significantly higher in the antibody-positive patients. In patients receiving infliximab or adalimumab therapy, the presence of antidrug antibodies was directly associated with reduced plasma TNF-inhibitor concentration and elevated plasma TNF-α level.
authors.affiliation: Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
authors.forename: Róbert
authors.identifier: http://orcid.org/0000-0002-9448-4573
authors.initials: R
authors.lastname: Kui
authors.affiliation: Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
authors.forename: Brigitta
authors.initials: B
authors.lastname: Gál
authors.affiliation: Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
authors.forename: Magdolna
authors.initials: M
authors.lastname: Gaál
authors.affiliation: Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
authors.forename: Mária
authors.initials: M
authors.lastname: Kiss
authors.affiliation: Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.|MTA-SZTE Dermatological Research Group, Szeged, Hungary.
authors.forename: Lajos
authors.initials: L
authors.lastname: Kemény
authors.affiliation: Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.|Department of Dermatology, Venereology and Oncodermatology, University of Pécs, Pécs, Hungary.
authors.forename: Rolland
authors.initials: R
authors.lastname: Gyulai
mesh_terms: D000068879:Adalimumab / Q000097:blood / Q000276:immunology* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D057134:Antibodies, Neutralizing / Q000097:blood*; D001691:Biological Therapy / Q000379:methods; D003430:Cross-Sectional Studies; D003879:Dermatologic Agents / Q000097:blood / Q000276:immunology* / Q000627:therapeutic use; D000068800:Etanercept / Q000097:blood / Q000276:immunology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000069285:Infliximab / Q000097:blood / Q000276:immunology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000097:blood*; D055815:Young Adult
chemical_list: D057134:Antibodies, Neutralizing; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept
keywords: adalimumab; antidrug antibodies; etanercept; infliximab; psoriasis